Related Experiment Videos
Predicting blood usage in cardiac surgery--the transfusion predictor product
Michael B McDonald1, James McMillan
1Monash Medical Centre, Clayton. mmcdonald@perfusionservices.com.au
The Journal of Extra-Corporeal Technology
|August 25, 2005
Summary
The Transfusion Predictor Product (TPP) can identify cardiac surgery patients unlikely to need intraoperative transfusions. This finding helps reduce unnecessary blood cross-matching and associated costs.
Area of Science:
- Cardiovascular Surgery
- Transfusion Medicine
- Anesthesiology
Background:
- Intraoperative transfusions in cardiac surgery are costly and often unnecessary.
- Dilution of red blood cells due to cardiopulmonary bypass is a primary cause of transfusion needs.
Purpose of the Study:
- To investigate the predictive ability of red blood cell volume for intraoperative transfusion requirements.
- To identify a reliable method for predicting the need for blood transfusion during cardiothoracic surgery.
Main Methods:
- Retrospective analysis of 401 cardiothoracic surgery patients requiring cardiopulmonary bypass.
- Calculation of the Transfusion Predictor Product (TPP) using body surface area and preoperative hemoglobin (gHb/l/m²).
- Comparison of transfusion rates between patients with TPP below and above a defined threshold.
Main Results:
- A TPP value below 211.7u was associated with a significantly higher rate of intraoperative transfusion (46% vs. 6%).
- Patients with a TPP greater than 211.7u had a low incidence of intraoperative red blood cell transfusion.
- The TPP effectively differentiates patients with low versus high transfusion risk.
Conclusions:
- Patients with a TPP > 211.7u may not require routine blood cross-matching for cardiac surgery.
- Individualized cross-matching based on predicted cardiopulmonary bypass duration and patient comorbidities is recommended for high-TPP patients.
- Implementing the TPP can optimize blood utilization and reduce healthcare costs in cardiac surgery.